AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HAEMONETICS CORP Director's Dealing 2025

May 19, 2025

31565_dirs_2025-05-19_dc8089f3-5d3b-4348-9a37-0526eb1748e1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2025-05-15

Reporting Person: Maunsell Farris Maryanne (VP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-15	Common Stock	F	60	$69.38	Disposed	1084	Direct
2025-05-16	Common Stock	F	68	$70.31	Disposed	1016	Direct

Footnotes

F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2: This number includes unvested RSUs previously reported.